Combined Phase 3, Double-blind, Randomized, Placebo-Controlled
Studies Evaluating the Efficacy and Safety of Filgotinib in the
Induction and Maintenance of Remission in Subjects with Moderately
to Severely Active Crohn’s Disease
Associated ConditionsInflammatory Bowel Disease (IBD)
You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib is effective and safe in treating people with moderate to severe Crohn’s disease
This study is currently enrolling.